Biopharmaceutical company focusing on liver and metabolic diseases.
Galmed Pharmaceuticals Ltd., headquartered in Tel Aviv, Israel, and founded in 2000, is a clinical-stage biopharmaceutical company dedicated to developing therapeutics for liver diseases. The company's lead product candidate, Aramchol, is an oral therapy currently in a Phase III clinical trial targeting non-alcoholic steatohepatitis (NASH) in overweight or obese patients who are pre-diabetic or have type-II diabetes mellitus. Additionally, Aramchol is being evaluated in the ARRIVE Study, a Phase IIa clinical trial for patients with HIV-associated non-alcoholic fatty liver disease and lipodystrophy.
Beyond Aramchol, Galmed is advancing the development of Amilo-5MER, a synthetic peptide comprising five amino acids: methionine, threonine, alanine, aspartic acid, and valine. The company's research initiatives include a partnership with Gannex Pharma Co., Ltd. to develop a combination therapy of ASC41 (a THR-beta agonist) and Aramchol (an SCD1 inhibitor) for NASH treatment. Furthermore, Galmed collaborates with MyBiotics Pharma Ltd. to identify microbiome repertoires associated with Aramchol response and holds a license agreement with Samil Pharma Co., Ltd. for Aramchol's commercialization in the Republic of Korea.
Galmed Pharmaceuticals Ltd. continues to focus on innovative research and strategic collaborations to address unmet medical needs in liver disease treatment. By leveraging its scientific expertise and robust pipeline, the company aims to bring effective therapeutic solutions to the market, enhancing patient care and driving shareholder value.